ESR1 and breast cancer: Moreover, after analyzing the groups according to HER2 expression, we reveal two distinct groups which give the ER−/PR+ subgroup a heterogeneity characterization; this breast cancer subtype should not be treated as a luminal tumor but rather according to the HER2 expression status.